SAN DIEGO, Aug. 6, 2009 (GLOBE NEWSWIRE) -- Vical Incorporated (Nasdaq:VICL) today reported financial results for the quarter ended June 30, 2009. Revenues increased to $4.0 million for the second quarter of 2009 from $2.5 million for the second quarter of 2008, primarily as a result of a $1.5 million milestone payment from Merck & Co., Inc., based on Merck’s ongoing Phase 1 clinical-stage development of an investigational cancer vaccine. Operating expenses declined to $9.8 million for the second quarter of 2009 from $11.4 million for the second quarter of 2008, primarily as a result of a strategic restructuring implemented in the fourth quarter of 2008. The net loss was $6.0 million, or $0.14 per share, for the second quarter of 2009, compared with $8.5 million, or $0.21 per share, for the second quarter of 2008.
